4-(4-甲氧基苯氧基)哌啶盐酸盐 | 333954-89-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(4-甲氧基苯氧基)哌啶盐酸盐
• 英文名称: 4-(4-methoxyphenoxy)piperidine hydrochloride
• 英文别名: 4-(4-methoxyphenoxy)piperidine· hydrochloride；4-(4-methoxyphenoxy)piperidine;hydrochloride
• CAS: 333954-89-5
• 化学式: C₁₂H₁₇NO₂*ClH
• mdl: MFCD03840124
• 分子量: 243.733
• InChiKey: QNAZHUIQLCZUJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(4-甲氧基苯氧基)哌啶盐酸盐 在 三溴化硼 作用下， 生成 4-(4-piperidyloxy)phenol
  参考文献：
  名称：

  PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF

  摘要：

  Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.

  公开号：

  US20240285614A1
• 作为产物：
  描述：

  4-甲氧基苯酚 在 盐酸 作用下， 生成 4-(4-甲氧基苯氧基)哌啶盐酸盐
  参考文献：
  名称：

  PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF

  摘要：

  Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.

  公开号：

  US20240285614A1

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20130324576A1

  公开（公告）日：2013-12-05

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R 1 , R 2 , R 3 and R 4 are as defined in the specification, for use in therapy.

  本发明提供了式(I)的化合物及其药学上可接受的盐，其中m、n、W、X、Y、Z、R、R1、R2、R3和R4如规范中定义，用于治疗。
• [EN] SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES<br/>[FR] DÉRIVÉS DE SULFONYLPIPÉRIDINE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR UNE PROKINÉTICINE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013179024A1

  公开（公告）日：2013-12-05

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatment or prevention of a diseases o conition mediated by a prokineticin, such as psychiatric and neurological conitions.

  本发明提供了以下式（I）的化合物及其药学上可接受的盐：（I）其中m、n、W、X、Y、Z、R1、R2、R3和R4如规范中定义，用于治疗或预防由前动力素介导的疾病或状况，如精神疾病和神经病状。
• SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150111922A1

  公开（公告）日：2015-04-23

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: (I) in which m, n, W, X, Y, Z, R 1 , R 2 , R 3 and R 4 are as defined in the specification, for use in the treatment or prevention of a diseases o conition mediated by a prokineticin, such as psychiatric and neurological conditions.

  本发明提供了公式（I）的化合物及其药学上可接受的盐：（I）其中m、n、W、X、Y、Z、R1、R2、R3和R4如规范中所定义，用于治疗或预防由前动力素介导的疾病或情况，例如精神和神经疾病。
• AMINE DERIVATIVES
  申请人：Tadeka Chemical Industries, Ltd.

  公开号：EP1227090A1

  公开（公告）日：2002-07-31

  A compound of the formula:    wherein X and X' are the same or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or an amino optionally having substituents, and at least one of X and X' represents a fluorine atom, a chlorine atom or an amino optionally having substituents; R1 and R2 represent a hydrogen atom or C1-6 alkyl optionally having substituents, or R1 and R2, together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring optionally having substituents; Y and Q are the same or different, and each represents a bond or a spacer having a main chain of 1 to 6 atoms; ... represents a single bond or a double bond; T1 and T2 are the same or different, and each represents C(R9) (R9 represents a hydrogen atom, a hydroxy or C1-6 alkyl) or N, when each of the adjacent ... is a single bond, and C when the adjacent ... is a double bond; and Ar represents an aromatic group optionally having substituents, a C3-9 cycloalkyl group optionally having substituents, a 3 to 9-membered saturated heterocyclic group optionally having substituents, a hydrogen atom or a halogen atom; provided that 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline; 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline and 1-benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide are excluded; a salt thereof or a prodrug thereof has an excellent somatostatin receptor binding inhibition action and is useful for preventing and/or treating diseases associated with somatostatin.

  式中的化合物 X和X'相同或不同，各自代表氢原子、氟原子、氯原子或可选具有取代基的氨基，且X和X'中至少有一个代表氟原子、氯原子或可选具有取代基的氨基； R1 和 R2 代表氢原子或任选具有取代基的 C1-6 烷基，或 R1 和 R2 与相邻的氮原子一起形成任选具有取代基的含氮杂环； Y 和 Q 相同或不同，各自代表主链为 1 至 6 个原子的键或间隔物； 代表单键或双键； T1 和 T2 相同或不同，当相邻......中的每一个为单键时，各自代表 C(R9)（R9 代表氢原子、羟基或 C1-6 烷基）或 N，当相邻......中的每一个为双键时，各自代表 C；以及 Ar 代表任选具有取代基的芳香基、任选具有取代基的 C3-9 环烷基、任选具有取代基的 3-9 元饱和杂环基、氢原子或卤素原子；条件是 6-氯-3-(R,S)-(N,N-二甲基氨基)甲基-1-[3-(吲哚-3-基)-2-[(R)-(4-苯基哌嗪-1-基)羰基氨基]丙酰基]-1,2,3,4-四氢喹啉；6-氯-3-(R,S)-(N,N-二甲基氨基)甲基-1-[3-(吲哚-3-基)-2-[(R)-4-(2-氧代-2,3-二氢-1H-苯并咪唑-1-基)哌啶甲酰氨基]丙酰基]-1,2,3,4-四氢喹啉不包括 1-苯甲酰基-N-[(R)-2-[6-氯-3-[(N,N-二甲基氨基)甲基]-1,2,3,4-四氢喹啉-1-基]-1-[3-(吲哚-3-基)丙酰基]-4-哌啶甲酰胺；其盐或其原药具有优异的抑制体生长抑素受体结合的作用，可用于预防和/或治疗与体生长抑素相关的疾病。
• Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US10167273B2

  公开（公告）日：2019-01-01

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.

  本发明提供了式 (I) 化合物及其药学上可接受的盐类 其中 q、R11、R12、R13 和 R14 如说明书中所定义，用于治疗。